On August 15th, NIH and CDC released the 2013 Omnibus NIH/CDC SBIR Solicitation (NOT-OD-12-137) due on November 13, 2012. The SBIR program is a set-aside program for small business concerns to engage in federal R&D with potential for commercialization.
The SBIR legislation requires the Public Health Service, HHS, and certain other Federal agencies to reserve 2.6 percent of their FY 2012 extramural research or R&D budgets for an SBIR program.
SBIR Phase I determines the scientific and technical feasibility and the potential for commercialization of the proposed research but not to exceed $150,000 for direct costs. Phase II is to continue the research or R&D efforts initiated in Phase I but not to exceed $1,000,000 for direct costs. Phase III helps small businesses pursue with non-SBIR funds, ways to commercialize the research funded in Phase and Phase II.
A few of the research topics contained in the solicitation are:
· (NIH) National Cancer Institute—Real-time integration of sensor and self-report data for clinical and research applications
· (NIH) National Institute on Drug Abuse—A mobile application to help patients take their medications as prescribed to improve medication adherence
· (CDC) Center for Global Health—Rapid screening tests to prevent congenital infections and ensure blood safety
· (CDC) National Center on Birth Defects and Developmental Disabilities—Smartphone application for global birth defects surveillance
· (CDC) National Center for Chronic Disease Prevention and Health Promotion—A mobile phone application for advancing teen pregnancy prevention
Go to http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-137.html to view the solicitation.
